Atrial Fibrillation Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Atrial Fibrillation stocks.

Recent Signals

Date Stock Signal Type
2021-04-16 ABIO New 52 Week Closing Low Bearish
2021-04-16 ABIO Lizard Bullish Bullish Day Trade Setup
2021-04-16 ABIO Hammer Candlestick Bullish
2021-04-16 BMY Pocket Pivot Bullish Swing Setup
2021-04-16 BMY Stochastic Reached Overbought Strength
2021-04-16 BMY Upper Bollinger Band Walk Strength
2021-04-16 BSGM Stochastic Reached Oversold Weakness
2021-04-16 BSGM Bollinger Band Squeeze Range Contraction
2021-04-16 MDT New 52 Week Closing High Bullish
2021-04-16 MDT New 52 Week High Strength
2021-04-16 MDT New Uptrend Bullish
2021-04-16 MDT Upper Bollinger Band Walk Strength
2021-04-16 MDT Pocket Pivot Bullish Swing Setup
2021-04-16 MIST Death Cross Bearish

Recent News for Atrial Fibrillation Stocks

Date Stock Title
Apr 18 BMY AACR 2021 highlights Eli Lilly’s new KRAS battle; Affimed’s Natural Killer cell therapy
Apr 16 MDT Medtronic plc (MDT) Conversation and Q&A with Medtronic's Cardiac Rhythm Management Business (Transcript)
Apr 16 BSGM BioSig Technologies (BSGM) Presents At 20th Annual Needham Virtual Healthcare Conference - Slideshow
Apr 16 BMY U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma....
Apr 16 BMY FDA approves Bristol's Opdivo as first-line gastric cancer treatment
Apr 16 BMY Latest Upgrades and Downgrades: Bristol-Myers Squibb, Splunk, Tesla
Apr 16 BMY Bristol-Myers Gastric-Cancer Treatment Cleared by FDA
Apr 16 ITGR Globus Medical (GMED) Simplifies Spine Surgery With CREO ONE
Apr 16 BMY The Smartest Stocks to Buy With $200 Right Now
Apr 15 BSGM BioSig expands commercial team in two strategic regions
Apr 15 BSGM BioSig Expands Commercial Team in Two Strategic Regions
Apr 15 MDT Medtronic (MDT) Boosts Diabetes Management via New Infusion Set
Apr 15 BMY Bristol Myers' (BMY) Opdivo Combo Gets EU Nod for First-Line RCC
Apr 15 BMY The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
Apr 15 MDT Medtronic Is Healing Hearts and Padding Portfolios
Apr 14 BMY Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Apr 14 BSGM BioSig upgrades capabilities for advanced cardiac signal analysis
Apr 14 BSGM BioSig Launches Enhanced Signal Processing Capabilities for Advanced Cardiac Signal Analysis Through its Electrophysiology Platform
Apr 14 MDT Medtronic launches its insulin delivery infusion set in Europe
Apr 14 MDT Medtronic Announces European Launch of World's First Infusion Set with Wear up to Seven Days to Help Reduce Burden for People with Diabetes

Atrial fibrillation (AF or A-fib) is an abnormal heart rhythm characterized by rapid and irregular beating of the atria. Often it starts as brief periods of abnormal beating which become longer and possibly constant over time. Often episodes have no symptoms. Occasionally there may be heart palpitations, fainting, lightheadedness, shortness of breath, or chest pain. The disease is associated with an increased risk of heart failure, dementia, and stroke. It is a type of supraventricular tachycardia.High blood pressure and valvular heart disease are the most common alterable risk factors for AF. Other heart-related risk factors include heart failure, coronary artery disease, cardiomyopathy, and congenital heart disease. In the developing world valvular heart disease often occurs as a result of rheumatic fever. Lung-related risk factors include COPD, obesity, and sleep apnea. Other factors include excess alcohol intake, tobacco smoking, diabetes mellitus, and thyrotoxicosis. However, half of cases are not associated with any of these risks. A diagnosis is made by feeling the pulse and may be confirmed using an electrocardiogram (ECG). A typical ECG in AF shows no P waves and an irregular ventricular rate.AF is often treated with medications to slow the heart rate to a near normal range (known as rate control) or to convert the rhythm to normal sinus rhythm (known as rhythm control). Electrical cardioversion can also be used to convert AF to a normal sinus rhythm and is often used emergently if the person is unstable. Ablation may prevent recurrence in some people. For those at low risk of stroke, no specific treatment is typically required, though aspirin or an anti-clotting medication may occasionally be considered. For those at more than low risk, an anti-clotting medication is typically recommended. Anti-clotting medications include warfarin and direct oral anticoagulants. Most people are at higher risk of stroke. While these medications reduce stroke risk, they increase rates of major bleeding.Atrial fibrillation is the most common serious abnormal heart rhythm. In Europe and North America, as of 2014, it affects about 2 to 3% of the population. This is an increase from 0.4 to 1% of the population around 2005. In the developing world, about 0.6% of males and 0.4% of females are affected. The percentage of people with AF increases with age with 0.1% under 50 years old, 4% between 60 and 70 years old, and 14% over 80 years old being affected. A-fib and atrial flutter resulted in 193,300 deaths in 2015, up from 29,000 in 1990. The first known report of an irregular pulse was by Jean-Baptiste de Sénac in 1749. This was first documented by ECG in 1909 by Thomas Lewis.

More about Atrial Fibrillation
Browse All Tags